In charge of overall operation of a innovation company which is leading in gene therapy.1. Led teams to accomplish Phase II clinical trials for the leading pipeline.2. Obtained 3 INDs.3. Secured funding of US$35 million.

In charge of overall operation of the company.1. Accomplished the market launch for the rabies vaccine. Annual sales reached US$25 million.2. Led teams to carry out Phase III clinical trials for one small molecule cancer therapy.3. Directed BD team to finalize 3 license-in projects.4. Initiated 7 first-in-class pre-clinical research.5. Accomplished 3 generic filing. Annual sales reached US$12 million.

Lead and manage 5 API and advanced intermediate production plants located in Zhejiang and Jiangsu provinces. Direct responsibility for production plan, cost control, quality control, tech transfer, process development and environmental trend. Total revenue: US$258 million.1. Accomplished annual production plan with revenue reached US$3 billion.2. Led Process R&D to accomplish 87 process development projects with US$16 million contribution on cost saving.3. Passed 2 FDA and 1 BGV GMP audits with zero deficient.4. Initiated the construction of a state-of-art process R&D center with various technology platforms including a new solid state lab, enzymatic catalyst lab, crystallization lab, etc.5. Developed new CMO business, accomplished 5 CMO projects with US$22 million revenue.

Responsible for technical aspect of CMO projects including production management, process R&D, cost control, organization structure. Responsible for customer relationship including business development and customer quality audit.1. Accomplished 87 projects, including advanced intermediate production and cGMP batches for clinical trials. Total revenue US$30 million.2. Assisted customers to accomplish 10 CMC package for FDA filings.3. quality system audit and led quality improvement program. Established API quality specification, including purity, impurity profile, impurity structure elucidation, physical properties.4. Participate 24 times business negotiations. Received 5 times quality audits from big pharmaceutical companies and once CFDA GMP audit.5. Initiated new SOP program.6. Participated API commercial manufacture plant validation.

Responsibility for process development, tech transfer, API manufacture to support market launch and commercial production.1. Led team to accomplish 5 antiviral NDA (Viread, Emtriva, Hepsera, Truvada and Atripla) filings and 10 IND filings. Viread, Truvada and Atripla achieved blockbuster status in the market with annual sale of US$2 billion, US$3.1 billion and US$3.5 billion, respectively.2. Managed API cGMP production to support clinical studies and accomplished 16 API process development projects.3. Participated 50 million budget pilot plant construction, provided tech support and conducted cGMP validation batch.4. Provided tech support for outside production partnership, assisted them to achieve 250-ton production capability for Viread.5. Assisted the sourcing effort on supply chain saving US$30 million cost on raw materials.6. Employee of the Year (2005).